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Abstract: Nonpathogenic Neisseria transfer mutations encoding antibiotic resistance to their
pathogenic relative Neisseria gonorrhoeae. However, the resistance genotypes and subsequent
phenotypes of nonpathogens within the genus have been described infrequently. Here, we characterize
the minimum inhibitory concentrations (MICs) of a panel of Neisseria (n = 26)—including several
commensal species—to a suite of diverse antibiotics. We furthermore use whole genome sequencing
and the Comprehensive Antibiotic Resistance Database Resistance Gene Identifier (RGI) platform
to predict putative resistance-encoding mutations. Resistant isolates to all tested antimicrobials
including penicillin (n = 5/26), ceftriaxone (n = 2/26), cefixime (n = 3/26), tetracycline (n = 10/26),
azithromycin (n = 11/26), and ciprofloxacin (n = 4/26) were found. In total, 63 distinct mutations
were predicted by RGI to be involved in resistance. The presence of several mutations had clear
associations with increased MIC such as DNA gyrase subunit A (gyrA) (S91F) and ciprofloxacin,
tetracycline resistance protein (tetM) and 30S ribosomal protein S10 (rpsJ) (V57M) and tetracycline,
and TEM-type β-lactamases and penicillin. However, mutations with strong associations to macrolide
and cephalosporin resistance were not conclusive. This work serves as an initial exploration into
the resistance-encoding mutations harbored by nonpathogenic Neisseria, which will ultimately
aid in prospective surveillance for novel resistance mechanisms that may be rapidly acquired
by N. gonorrhoeae.
Keywords: resistome; commensal bacteria; horizontal gene transfer; antibiotic resistance;
microbiome; Neisseria
1. Introduction
The emergence of antibiotic resistance in pathogenic bacteria presents a challenge for successful
treatment of infections and is a global threat to public health. In the United States alone,
antibiotic-resistant bacteria cause an estimated 2.8 million infections and 35,000 deaths each year [1].
While resistance can arise in bacteria via de novo mutations, it can also be horizontally transferred from
environmental [2–4], animal [5–7], or human-associated [8–10] microbial communities. Thus, profiling
the resistome, or the collection of all antibiotic resistance mechanisms available to particular bacterial
species [4], is an important step in prospective surveillance for novel resistance-encoding mutations
that may be rapidly acquired by pathogens.
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There are a number of mechanisms that are employed by bacteria to circumvent the efficacy of
antibiotics. These include but are not limited to decreased drug influx, target modification, antibiotic
degradation, and increased efflux through pumps [11]. The threat of rapid resistance acquisition
via horizontal gene transfer (HGT) of all these mechanisms is exponentially amplified in bacteria
that are naturally competent and highly recombinogenic such as the Neisseria. The genus Neisseria
is composed of several closely related Gram-negative species, which are typically isolated from the
naso- and oropharynx of humans and animals. While most species are considered commensals or
“accidental pathogens”, only one, N. gonorrhoeae, is an obligate human pathogen which colonizes
the additional sites of the urogenital tract and rectum and causes the sexually transmitted infection
gonorrhea. Concerningly, antimicrobial resistance is an increasing problem within N. gonorrhoeae, with
over half of all 550,000 reported infections in the U.S. in 2017 resistant to at least one antibiotic [1]
and with treatment failing for the recommended azithromycin and ceftriaxone combination therapy
reported internationally as of 2018 [12,13].
One of the likely reasons for the high prevalence of resistance in N. gonorrhoeae is due to its natural
competence for transformation, preferentially with Neisseria-specific DNA, allowing for extensive
intragenus gene exchange and quick access to new adaptive solutions [14]. Gene acquisition from
commensal Neisseria is evidenced by widespread genomic mosaicism in N. gonorrhoeae, whereby specific
mutations or haplotypes have been shown to have been inherited from its close relatives [15–19].
Furthermore, mutations encoding resistance to both azithromycin [10,20] and third-generation
cephalosporins [21,22] have been demonstrated to have been transferred from nonpathogenic Neisseria
to N. gonorrhoeae. Ultimately, these documented cases of widespread gene exchange between the
Neisseria highlights the importance of surveying nonpathogenic members of the genus for the resistance
mechanisms that they harbor and may potentially share with their pathogen relative.
In this study, we set out to document both phenotypic and genotypic resistance across a panel of
commensal Neisseria acquired from the Centers for Disease Control and Prevention (CDC) and Food
and Drug Association’s (FDA) Antibiotic Resistance (AR) Isolate Bank, a bacterial strain collection
resource for studying antibiotic resistance [23]. We phenotype this panel (n = 26) to multiple classes
of antimicrobials (beta-lactams, a macrolide, fluoroquinolone, and tetracycline) and report their
minimum inhibitory concentrations (MIC). To link any observed increases in resistance to the possible
underlying genetic contributors, we furthermore sequence the genomes of these isolates and use the
Comprehensive Antibiotic Resistance Database (CARD) Resistance Gene Identifier (RGI) platform to
predict possible causal resistance-encoding mutations.
2. Results
2.1. Characterization of Phenotypic Resistance in the AR Isolate Bank Neisseria Panel
A total of 26 Neisseria isolates were obtained from the CDC and FDA’s AR Isolate Bank from
the Neisseria species MALDI-TOF verification panel (Table 1). Characterization of antimicrobial
susceptibility to penicillin, ceftriaxone, cefixime, tetracycline, azithromycin, and ciprofloxacin was
conducted using the Etest method (Table 1). For the gonococci within the panel (n = 6), three were
resistant to multiple antibiotic classes. N. gonorrhoeae AR Bank # 0936 was resistant to tetracycline and
ciprofloxacin and was just below the reduced susceptibility threshold for azithromycin (1.5 µg/mL
with the breakpoint at 2 µg/mL); N. gonorrhoeae AR Bank # 0937 was resistant to penicillin and
ciprofloxacin and was just below the reduced susceptibility threshold for tetracycline (1.5 µg/mL with
the breakpoint at 2 µg/mL); and N. gonorrhoeae AR Bank # 0938 was resistant to penicillin, tetracycline,
and ciprofloxacin.
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Table 1. Minimum inhibitory concentrations of Neisseria spps. measured by Etest.
Minimum Inhibitory Concentration (MIC) a,b











AR-0933 Neisseria gonorrhoeae 0.19 0.004 <0.016 1.5 0.25 0.004
AR-0934 Neisseria gonorrhoeae 0.38 0.016 0.023 1.5 0.125 0.006
AR-0935 Neisseria gonorrhoeae 0.19 0.006 <0.016 0.75 0.064 0.006
AR-0936 Neisseria gonorrhoeae 0.38 0.047 <0.016 2 1.5 >32
AR-0937 Neisseria gonorrhoeae >32 0.016 <0.016 1.5 0.38 6
AR-0938 Neisseria gonorrhoeae >32 0.008 <0.016 32 0.094 4
AR-0943 Neisseria bacilliformis 32 16 0.5 4 4 6
AR-0944 Neisseria cinerea 0.38 0.094 <0.016 2 8 0.032
AR-0945 Neisseria elongata 0.25 0.094 0.032 0.38 0.5 0.25
AR-0946 Neisseria lactamica 0.75 0.023 0.25 0.75 1.5 0.008
AR-0947 Neisseria oralis 1.5 0.047 0.064 1.5 1.5 0.016
AR-0948 Neisseria canis 0.25 0.008 <0.016 0.5 0.38 0.008
AR-0949 Neisseria macacae 1.5 0.064 0.064 2 8 0.125
AR-0950 Neisseria macacae 3 0.047 0.125 3 8 0.032
AR-0951 Neisseria mucosa 0.25 0.032 0.125 1 3 0.023
AR-0952 Neisseria macacae 0.38 0.023 0.047 2 0.5 0.012
AR-0953 Neisseria subflava 1.5 0.019 0.38 0.5 2 0.75
AR-0954 Neisseria subflava 3 0.25 0.5 48 4 0.047
AR-0955 Neisseria subflava 1 0.032 0.064 6 12 0.125
AR-0956 Neisseria subflava 1.5 0.125 0.25 1 6 0.75
AR-0957 Neisseria subflava 1 0.047 0.064 4 8 0.064
AR-0958 Neisseria weaveri 0.38 0.064 0.047 0.5 0.25 0.006
AR-0959 Neisseria weaveri 1 0.19 0.023 0.75 0.75 0.023
AR-0960 Kingella denitrificans 0.32 0.064 0.25 0.75 2 0.094
AR-0961 Moraxella catarrhalis 0.19 1 2 0.5 0.25 0.094
AR-0962 Moraxella catarrhalis 0.094 0.012 0.064 0.75 0.25 0.125
a Reported minimum inhibitory concentrations (MICs) are the mode of n = 3 replicates. b Isolates with reduced
susceptibilities are indicated by bold and underlined MIC values (Clinical & Laboratory Standards Institute (CLSI)
breakpoints: Penicillin (PEN) ≥ 2 µg/mL; Ceftriaxone (CRO) ≥ 0.5 µg/mL; Cefixime (CFX) ≥ 0.5 µg/mL; Tetracycline
(TET) ≥ 2 µg/mL; Azithromycin (AZI) ≥ 2 µg/mL; and Ciprofloxacin (CIP) ≥ 1 µg/mL).
Of the typically human-associated commensal Neisseria within the panel (n = 11), eight displayed
reduced susceptibly to at least one of the tested antibiotics (Table 1). Two isolates were resistant
to penicillin (N. bacilliformis AR Bank # 0943 and N. subflava AR Bank # 0954), one was resistant to
ceftriaxone (N. bacilliformis AR Bank # 0943), two were resistant to cefixime (N. bacilliformis AR Bank
# 0943 and N. subflava AR Bank # 0954), five were resistant to tetracycline (N. bacilliformis AR Bank # 0943,
N. cinerea AR Bank # 0944, N. subflava AR Bank # 0954, N. subflava AR Bank # 0955, and N. subflava AR
Bank # 0957), eight were resistant to azithromycin (N. bacilliformis AR Bank # 0943, N. cinerea AR Bank
# 0944, N. mucosa AR Bank # 0951, and N. subflava AR Bank # 0953 through 0957), and one was resistant
to ciprofloxacin (N. bacilliformis AR Bank # 0943). Only one isolate was resistant to all tested antibiotics,
N. bacilliformis AR Bank # 0943, which was the only representative of N. bacilliformis in the panel.
This isolate also had a high MIC to ceftriaxone of 16 µg/mL, with recorded MICs for N. gonorrhoeae,
typically ≤1 µg/mL [22]. Two out of the three isolates of the other represented human-associated
Neisseria (Moraxella and Kingella) showed reduced susceptibility to azithromycin (K. denitrificans AR
Bank # 0960) or to ceftriaxone and cefixime (M. catarrhalis AR Bank # 0961).
For the Neisseria typically associated with animals (N. canis, N. macacae, and N. weaveri; n = 6),
three were resistant to at least one antibiotic (Table 1); N. macacae AR Bank # 0949 was resistant to
tetracycline and azithromycin and was just below the reduced susceptibility threshold for penicillin
(1.5 µg/mL with the breakpoint at 2 µg/mL); N. macacae AR Bank # 0950 was resistant to penicillin,
tetracycline, and azithromycin; and N. macacae AR Bank # 0952 was resistant to tetracycline.
2.2. Genome Assemblies and Computational Analyses
Of the 26 isolates within our panel, we were able to generate genomic libraries for 24 of them
(Table 2). For the remaining isolates, N. cinerea AR Bank # 0944 and K. denitrificans AR Bank # 0960,
we were unable to generate sufficient DNA for sequencing. Genome assemblies ranged from 1.76
to 2.9 Mbp long and contained between 1684 to 2749 predicted open reading frames. Coverages
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ranged from 214x to 921x. All of the sequenced AR Bank isolates clustered with representatives of
their own species as assessed via a phylogeny generated from 16S rRNA gene sequences (Figure 1).
However, representatives of N. mucosa (n = 3) and N. macacae (n = 3) formed a single monophyletic cluster.
Table 2. Genome assembly statistics for sequenced strains.
Isolate SRA ReadAccession
Genome









AR-0933 SAMN15454039 2,100,787 52.6 65 438 2059 52
AR-0934 SAMN15454040 2,102,184 52.7 64 458 2081 49
AR-0935 SAMN15454041 2,215,614 52.35 54 470 2224 51
AR-0936 SAMN15454042 2,158,950 52.38 71 380 2117 50
AR-0937 SAMN15454043 2,138,399 52.53 69 498 2102 49
AR-0938 SAMN15454044 2,152,496 52.5 71 491 2124 49
AR-0943 SAMN15454045 2,342,297 59.34 91 421 2151 52
AR-0945 SAMN15454046 2,572,594 53.81 45 214 2511 55
AR-0946 SAMN15454047 2,145,323 52.48 53 366 1994 54
AR-0947 SAMN15454048 2,497,075 52.8 19 247 2302 56
AR-0948 SAMN15454049 2,399,311 48.41 42 341 2261 52
AR-0949 SAMN15454050 2,938,382 50.84 98 228 2749 58
AR-0950 SAMN15454051 1,762,877 51.47 18 344 2184 55
AR-0951 SAMN15454052 2,580,111 51.1 98 295 2330 54
AR-0952 SAMN15454053 2,446,961 51.04 66 319 2216 53
AR-0953 SAMN15454054 2,201,301 49.57 16 921 2096 54
AR-0954 SAMN15454055 2,359,025 49.13 57 390 2276 54
AR-0955 SAMN15454056 2,188,966 49.37 16 327 2033 55
AR-0956 SAMN15454057 2,238,415 49.02 34 397 2106 55
AR-0957 SAMN15454058 2,187,919 49.37 15 326 2029 55
AR-0958 SAMN15454059 2,268,810 49.1 30 478 2132 49
AR-0959 SAMN15454060 2,148,848 49.01 24 382 1962 49
AR-0961 SAMN15454061 1,882,811 41.81 13 577 1728 44
AR-0962 SAMN15454062 1,843,431 41.64 12 432 1684 43
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Figure 1. Maxi u likelihood phylogenetic tree of 38 Neisseria isolates based on the 16S rRNA
gene: species are coded by unique colors. The scale bar represents 0.08 substitutions per nucleotide
site. Antibiotic Resistance (AR) Bank # 0961, one of the Moraxella catarrhalis in the Neisseria species
MALDI-TOF verification panel, was used as an outgroup.
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In total, 279 total mutations or haplotypes predicted to encode resistance were found across all
sequenced isolates—consisting of 63 unique genetic mechanisms (Figure 2 and Supplementary Table S1).
These polymorphisms were predicted to encode resistance to 14 different classes of antimicrobial
compounds and included predicted phenotypic resistance to all tested drugs within this study.
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Figure 2. Heatmap showing the distribution of Comprehensive Antibiotic Resistance Database (CARD)
Resistance Gene Identifier (RGI) predicted resistance-encoding mutations for all sequenced isolates
(n = 24). Upper panel: Neisseria species’ susceptibility phenotypes as quantified by MIC. Black denotes
loss of susceptibility (CLSI standards), grey denotes one dilution below the reduced susceptibility
breakpoint, and white denotes susceptibility to the antibiotics listed on the right (PEN, penicillin; CRO,
ceftriaxone; CFX, cefixime; TET, tetracycline; AZI, azithromycin; and CIP, ciprofloxacin). Lower panel:
presence of each recovered mutation is indicated by blue fill. CARD-predicted resistance phenotypes
for sets of mutations are denoted for beta-lactam resistance (red shading), beta-lactam and tetracycline
resistance (purple), tetracycline (blue), macrolides (orange), fluoroquinolones (green), and resistance to
other antibiotics (grey).
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2.3. Quinolone Reduced Susceptibility
Resistance to quinolones like ciprofloxacin in gonococci is mediated by mutations that reduce
binding affinity to the primary drug target, DNA gyrase subunit A (GyrA)—a type II topoisomerase
that negatively supercoils ds-DNA. Specifically, these mutations include either a missense mutation
at codon 91 in gyrA (S91F) or codon 95 (D95N), which have nearly perfect sensitivity and specificity
for the prediction of resistance to this drug in clinical N. gonorrhoeae specimens [22,24–27]. In our
panel, we documented four isolates with reduced susceptibility to ciprofloxacin (N. gonorrhoeae AR
Bank # 0936 through 0938 and N. bacilliformis AR Bank # 0943), and unsurprisingly, they all had
either the GyrA S91F or D95N substitutions (Figure 2). However, interestingly, we also found two
N. subflava isolates (AR Bank # 0953 and AR Bank # 0956) with ciprofloxacin MICs less than one
dilution below the reduced susceptibility threshold (Table 1) which did not harbor these mutations.
Instead, they had a missense mutation at codon 83 in gyrA (T83I), which is located in a quinolone
resistance-determining region (QRDR) and has been shown to moderately increase quinolone resistance
in Pseudomonas aeruginosa [28].
2.4. Macrolide Resistance
Macrolide class antibiotics obstruct protein synthesis by binding to the 50S ribosomal subunit,
and within N. gonorrhoeae, several types of mutations have been documented to be involved in
resistance. These mutations include substitutions in the 23S rRNA azithromycin binding sites (C2611T
and A2059G) [29,30], the presence of mosaic multiple transferable resistance (mtr) efflux pump alleles
acquired from commensal Neisseria species [10,20,22,31], mutations that increase the expression of
mtrCDE [32–34], mutations in rplD [22], rplV tandem duplications [22], and variants of the rRNA
methylase genes ermC and ermB [35]. However, we found no isolates in this panel with any of these
mutations above the Clinical & Laboratory Standards Institute (CLSI) reduced susceptibility breakpoint
(Figure 2). We did find four N. gonorrhoeae isolates with missense mutations at codons 39 (A39T) and
45 (G45D) of the repressor of the Mtr efflux pump (MtrR), which have been shown to enhance mtrCDE
expression by introducing radical amino acid substitutions in the DNA-binding motif of the repressor
and by ablating its promoter-binding function [32,36]. However, these isolates did not have elevated
MICs to azithromycin.
2.5. Reduced Susceptibility to Tetracycline
Tetracycline is a broad-spectrum polyketide antibiotic that binds the bacterial 30S ribosomal
subunit and blocks incoming aminoacyl tRNAs from entering the ribosome acceptor site. Here, we
found two isolates N. gonorrhoeae AR Bank # 0938 and N. subflava AR Bank # 0954 with high-level
tetracycline resistance (≥32 µg/mL; Table 1). High-level tetracycline resistance in Neisseria has been
demonstrated to be a direct result of inheritance of a class M tetracycline resistance determinant
(encoded by tetM), which after binding to the ribosome triggers the release of tetracycline due to its
resemblance to elongation factor G (EF-G). Both N. gonorrhoeae AR Bank # 0938 and N. subflava AR
Bank # 0954 had a tetM gene present (Figure 2), further supporting prior literature suggesting that tetM
circulates within commensal Neisseria communities [37] in addition to gonococcal populations [38,39].
Lower level tetracycline resistance has been shown to be mediated by mutations that decrease the
influx of tetracycline through porin [40,41], mutations in mtr that increase pump expression [41–43],
or structure-modifying mutations in the ribosome [44]. Several isolates had mutations in the porin
(PorB G120K, A121D, or A121N) and/or mutations in the ribosomal protein RpsJ (V57M), which have
previously been associated with reduced susceptibility to tetracycline in previous studies [40,44];
however, inheritance of these mutations were not perfectly correlated with reduced susceptibility
(Figure 2).
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2.6. Resistance to β-Lactams
Penicillins (penicillin G) and cephalosporins (ceftriaxone and cefixime) are β-lactam antibiotics
which inhibit cell wall biosynthesis by binding the transpeptidase enzymes (penicillin-binding proteins
(PBPs)) that form the peptidoglycan cross-links in the bacterial cell wall. High-level penicillin resistance
in gonococci is typically mediated by the presence of a TEM-1-type β-lactamase encoded by the blaTEM-1
gene, which acts through degradation of the four-atom β-lactam ring of penicillin [45]. Of the isolates
within this panel with penicillin MICs ≥ 32 µg/mL, two out of three had a TEM-type β-lactamase
present. Lower level penicillin resistance can be modulated through multiple mutations including those
in penA [41,46], mtr and its regulatory components [41–43], porB [40,41], ponA [47], and pilQ [47,48],
which often contribute additively to one another [47]. Notably within the commensals in this panel,
we found at least one of these mutations present in all isolates (i.e., porB G120K, A121D, or A121N;
ponA L421P; or several mutations in penA (Figure 2)), suggesting their widespread availability for
horizontal exchange.
In contrast to the multiple mutations that give rise to penicillin resistance, reduced susceptibility
to cephalosporins in Neisseria is most frequently mediated by mutations in the PBP targets of the drug
which decrease their acylation rate. Commensal Neisseria spps. are proven sources of alleles conferring
cephalosporin resistance for N. gonorrhoeae, and within this panel, we found penA alleles with several
amino acid substitutions that have been proven or associated with increased resistance including
A311V, I312M, V316T, V316P, A501T, G542S, and P551L [21,49–51] (Figure 2). Finally, we found a
BRO-1 β-lactamase in one of the Moraxella catarrhalis isolates (AR Bank # 0961) within the panel which
also was resistant to both cefixime and ceftriaxone (Table 1 and Figure 2). The BRO-1 β-lactamase has
previously been associated with resistance to β-lactams and is present in over 90% of all M. catarrhalis
isolates [52,53], though it is unclear if this β-lactamase can be transferred to the other Neisseria.
3. Discussion
The significance of the commensal Neisseria as reservoirs of antibiotic resistance for gonococci has
been repeatedly demonstrated [10,20–22,49–51], which emphasizes the importance of characterizing
mutations encoding reduced susceptibility across the entirety of this species consortium. Our results
offer an initial exploration into the Neisseria resistome and clearly demonstrate resistance-encoding
mutations that are known in gonococci (gyrA (S91F), tetM, and TEM-type β-lactamases) to also
circulate in commensal communities, suggesting their widespread availability for horizontal transfer.
However, it is also clear that we have not captured all mutations involved in producing reduced
susceptibility across this panel. This is evidenced by isolates with the same reported resistance
haplotypes displaying variation in MIC. For example, N. subflava AR Bank # 0954 and 0955 had MICs to
penicillin of 3 and 1 µg/mL, respectively, despite having the same mutations in penA and porB (Table 1
and Figure 2). Similarly, N. gonorrhoeae AR Bank # 0936 and 0937 isolates had ciprofloxacin MICs of
32 and 6 µg/mL, respectively, yet harbored the same gyrA (S91F) substitution (Table 1 and Figure 2).
Furthermore, there are cases of unexplained resistance for which no putative resistance mutations had
been identified—especially for the drug azithromycin. However, this is not necessarily surprising
for macrolide antibiotics, as much of the genetic basis of resistance remains unclear in gonococci [22],
suggesting that many mutational steps are required and that there may be many different paths to
reduced susceptibility. Ultimately, these discrepancies between phenotype and genotype point to the
main limitations of our approach, which include the dependence on a database that contains the full
universe of polymorphisms within a given species or genus that may give rise to resistance, sufficient
sequence homology between database entries and query sequences for alignment, and knowledge
of epistatic modulators of resistance that may not directly impact MIC on their own but only in
combination with other mutations.
Though lab-based efforts will be needed to confirm the causality of our CARD-nominated
mutations in reduced susceptibility in addition to the elucidation of the genetic underpinnings that to
contribute to the unexplained MIC variance, our combined approaches employing both experimental
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quantification of MIC data coupled with genomic sequencing is a key first step in exploring the possible
resistance mechanisms harbored by commensal populations. Ultimately, these types of studies will
provide the foundation for prospective surveillance of novel resistance determinants that may be
rapidly acquired by pathogens of critical importance across a wide range of genera.
4. Materials and Methods
4.1. Bacterial Strains and Culture Conditions
All isolates were cultured on GC agar base medium (Becton Dickinson Co., Franklin Lakes, NJ,
USA) supplemented with 1% Kellogg’s solution (GCB-K plates) [54] at 37 ◦C in a 5% CO2 incubator.
Stocks for all bacteria were stored at −80 ◦C in trypticase soy broth containing 50% glycerol.
4.2. Minimum Inhibitory Concentration Testing
Antimicrobial susceptibility testing was conducted using Etest strips on GCB-K plates, according
to the manufacturer specifications (bioMérieux, Durham, NC, USA), which have been shown to have
comparable MIC values to the agar dilution method, with the exception of cefixime for which Etests
systemically report lower MICs [55]. In brief, cells from overnight plates were suspended in trypticase
soy broth to a 0.5 McFarland standard and inoculated onto new GCB-K plates. Etest strips were
subsequently placed on the surface of the inoculated plates. Following 18–24 h of incubation at 37 ◦C in
a 5% CO2 incubator, MICs were determined by reading the lowest concentration that inhibited growth,
and reduced susceptibility was determined using CLSI guidelines (CLSI breakpoints: penicillin (PEN)
≥ 2 µg/mL; ceftriaxone (CRO) ≥ 0.5 µg/mL; cefixime (CFX) ≥ 0.5 µg/mL; tetracycline (TET) ≥ 2 µg/mL;
azithromycin (AZI) ≥ 2 µg/mL; and ciprofloxacin (CIP) ≥ 1 µg/mL) [56]. Intermediate MIC values
are defined for penicillin, tetracycline, and ciprofloxacin at PEN ≥ 0.12 µg/mL, TET ≥ 0.5 µg/mL, and
CIP ≥ 0.12 µg/mL, respectively [56]. MICs were read by at least two independent researchers, and the
mode of three tests was reported.
4.3. Library Preparation and Genomic Sequencing
Genomic DNA was isolated by lysing growth from overnight plates in TE buffer (10 mM Tris
(pH 8.0), 10 mM EDTA) with 0.5 mg/mL lysozyme and 3 mg/mL proteinase K (Sigma-Aldrich Corp.,
St. Louis, MO, USA). To obtain sufficient DNA from AR BANK # 0943 and AR BANK # 0958, which
were difficult to swab off of GCB-K plates, we instead inoculated liquid GCB broth media (7.5 g protease
peptone #3, 0.5 g soluble starch, 2 g dibasic K2HPO4, 0.5 g monobasic KH2PO4, 2.5 g NaCl, and ddH2O
to 500 mL; Becton Dickinson) supplemented with 1% Kellogg’s solution and incubated overnight at
37 ◦C. After 24 h, cultures were centrifuged for 10 min at 14,000 rpm. The supernatant was discarded,
and the same method as described above was used to isolate DNA.
DNA was purified using the PureLink Genomic DNA Mini kit (Thermo Fisher Corp., Waltham,
MA, USA), treated with RNase A, and stored in water. Sequencing libraries were prepared using
the Nextera XT kit as per the manufacturer’s instructions (Illumina Corp., San Diego, CA, USA).
Samples were uniquely dual-indexed, pooled (n = 17–18 libraries per pool), and sequenced using a V3
600 cycle cartridge (2 × 300 bp) on an Illumina MiSeq platform at the Rochester Institute of Technology
Genomics Core.
4.4. Genome Assembly and Bioinformatic Analyses
Sequencing quality of each paired-end read library was assessed using FastQC v0.11.9 [57].
Trimmomatic v0.39 [58] was used to trim adapter sequences and to remove bases with phred quality
score < 15 over a 4-bp sliding window. Reads < 36 bp long or those missing a mate were also removed
from subsequent analysis. Trimmed reads were assembled using SPAdes v.3.7.0 [59], and the resultant
de novo assemblies were evaluated using the Quality Assessment Tool for Genome Assemblies
(QUAST) v.4.1 [60]. Prokka v.1.11 [61] was used to annotate assemblies. Resistance-encoding mutations
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were predicted using the Comprehensive Antibiotic Resistance Database (CARD) Resistance Gene
Identifier (RGI) v5.1.0 [62]. Gene presence or absence was not considered, unless tetM or TEM beta
lactamases were recorded, which are most often harbored on plasmids [63].
To assess evolutionary relationships between isolates, we used the annotated 16s rRNA gene in
FA1090 (AE004969.1) as a reference and subset the homologous region in each assembly with blastn.
We then used CLC Main Workbench v20.0.4 [64] to align sequences and to reconstruct a maximum
likelihood phylogeny using 100 bootstrap replicates and the Jukes Cantor substitution model.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/10/656/s1,
Table S1: CARD RGI predicted resistance mutations for each sequenced isolate in the study (n = 24), Table S2:
Accessions for the Neisseria used in the Figure 1 16S phylogeny.
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